Witt, S H
Juraeva, D
Sticht, C
Strohmaier, J
Meier, S
Treutlein, J
Dukal, H
Frank, J
Lang, M
Deuschle, M
Schulze, T G
Degenhardt, F
Mattheisen, M
Brors, B
Cichon, S
Nöthen, M M
Witt, C C
Rietschel, M
Article History
Received: 18 June 2014
Accepted: 23 June 2014
First Online: 19 August 2014
Competing interests
: Michael Deuschle and his research group have received speaker and consulting fees from BristolMyers Squibb, Otsuka Pharma, and Servier. Michael Deuschle is a national coordinator and principal investigator of phase II and III trials for Lilly Pharma and Roche. The remaining authors declare no conflict of interest.